ILIADIN Nasal Drops Soln 0.05 %w/v

Land: Irland

Sprache: Englisch

Quelle: HPRA (Health Products Regulatory Authority)

Wirkstoff:

OXYMETAZOLINE HYDROCHLORIDE

Verfügbar ab:

Seven Seas Ltd

Dosierung:

0.05 %w/v

Darreichungsform:

Nasal Drops Soln

Berechtigungsdatum:

1994-04-01

Fachinformation

PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Iliadin 0.05% w/v Nasal Drops, Solution.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Oxymetazoline Hydrochloride 0.05% w/v.
For excipients, see 6.1
3 PHARMACEUTICAL FORM
Nasal drops, solution.
A clear, colourless solution.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
For the relief of nasal congestion associated with disorders of the upper respiratory tract including
infective and allergic 
rhinitis, sinusitis, nasopharyngitis and coryza
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
Adults and children over the age of 6 years.
2-3 drops into each nostril every 8 to 12 hours
Intranasally
4.3 CONTRAINDICATIONS
Use in patients with known hypersensitivity to sympathomimetics.
Use in patients receiving monoamine oxidase inhibitors or within
fourteen days of stopping such treatment.
Use  in  acute  coronary  disease,  cardiac  asthma,  thyrotoxicosis,  hypertension,  closed-angle  glaucoma  or  urinary 
retention.
Use in children under 6 years of age.
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
Use with great care in patients suffering from angina and
digitalized patients.
This  product  should  be  given  with  care  to  patients  with  prostatic  enlargement,  as  it  may  increase  difficulty  in 
micturition.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Issued 10/08/2005_
_CRN 2013409_
_page number: 1_
Prolonged use may cause rebound congestion and drug induced
rhinitis.
Use with caution in diabetic patients as this product may
cause an increase in blood sugar.
The  physician  or  pharmacist  should  reassure  himself/herself  sympathomimetic  containing  preparations  are  not 
simultaneously administered by several routes i.e. orally and
topically